Amsurg Corp. (NASDAQ:AMSG)‘s stock had its “positive” rating reiterated by research analysts at KeyCorp in a report released on Tuesday. They currently have a $87.00 price target on the stock. KeyCorp’s price target would indicate a potential upside of 29.91% from the stock’s previous close.
Other analysts have also issued research reports about the company. Mizuho upped their target price on Amsurg Corp. from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, June 24th. Bank of America Corp. raised Amsurg Corp. from a “neutral” rating to a “buy” rating and set a $104.00 target price for the company in a research note on Thursday, June 16th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $95.00 target price on shares of Amsurg Corp. in a research note on Thursday, July 14th. Wells Fargo & Co. assumed coverage on Amsurg Corp. in a research note on Tuesday, June 14th. They issued a “market perform” rating for the company. Finally, Zacks Investment Research lowered Amsurg Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $92.09.
Shares of Amsurg Corp. (NASDAQ:AMSG) opened at 66.97 on Tuesday. The company has a market cap of $3.60 billion, a price-to-earnings ratio of 19.87 and a beta of 0.68. Amsurg Corp. has a 1-year low of $58.37 and a 1-year high of $87.29. The stock has a 50 day moving average of $65.51 and a 200 day moving average of $73.40.
Amsurg Corp. (NASDAQ:AMSG) last issued its earnings results on Tuesday, August 2nd. The company reported $1.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.02. The business earned $758.50 million during the quarter, compared to analyst estimates of $769.88 million. Amsurg Corp. had a return on equity of 8.20% and a net margin of 6.53%. Amsurg Corp.’s revenue for the quarter was up 21.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.97 earnings per share. Analysts predict that Amsurg Corp. will post $4.33 EPS for the current year.
In related news, insider Robert Jon Coward sold 7,500 shares of the company’s stock in a transaction that occurred on Friday, August 26th. The stock was sold at an average price of $63.65, for a total transaction of $477,375.00. Following the completion of the transaction, the insider now owns 97,507 shares in the company, valued at $6,206,320.55. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.30% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Calvert Investment Management Inc. increased its position in Amsurg Corp. by 0.9% in the second quarter. Calvert Investment Management Inc. now owns 3,180 shares of the company’s stock worth $247,000 after buying an additional 29 shares during the period. Howe & Rusling Inc. increased its position in Amsurg Corp. by 0.8% in the second quarter. Howe & Rusling Inc. now owns 8,695 shares of the company’s stock worth $674,000 after buying an additional 65 shares during the period. Northwestern Mutual Investment Management Company LLC increased its position in Amsurg Corp. by 1.0% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 9,334 shares of the company’s stock worth $724,000 after buying an additional 93 shares during the period. GHP Investment Advisors Inc. increased its position in Amsurg Corp. by 1.0% in the second quarter. GHP Investment Advisors Inc. now owns 15,875 shares of the company’s stock worth $1,231,000 after buying an additional 155 shares during the period. Finally, Raymond James Trust N.A. increased its position in Amsurg Corp. by 4.6% in the second quarter. Raymond James Trust N.A. now owns 5,042 shares of the company’s stock worth $391,000 after buying an additional 223 shares during the period. Institutional investors own 98.42% of the company’s stock.
Amsurg Corp. Company Profile
AmSurg Corp. is a surgical center and physician services company. The Company is an owner and operator of ambulatory surgery centers (ASCs) in the United States. The Company is also a provider of outsourced physician services in the areas of anesthesiology, children’s services, emergency medicine and radiology.
Receive News & Ratings for Amsurg Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amsurg Corp. and related companies with MarketBeat.com's FREE daily email newsletter.